[Skip to Content]
[Skip to Content Landing]
Letters
November 20, 1987

Colestipol-Niacin Therapy and Coronary Atherosclerosis

JAMA. 1987;258(19):2695. doi:10.1001/jama.1987.03400190076019
Abstract

To the Editor.—  The encouraging initial results from the Cholesterol-Lowering Atherosclerosis Study (CLAS)1 provide a strong impetus to larger and longer studies that can focus on different outcomes (eg, total occlusion) and quantify changes on sequential coronary angiograms. As Dr Passamani2 wrote in the editorial accompanying the report, promising areas for further research include newer lipid-lowering regimens and larger reductions in low-density lipoprotein cholesterol levels.Blankenhorn et al could usefully expand on the CLAS results in two ways: first, with additional data on the baseline comparability of the two treatment groups; and second, with additional information on the global coronary change score, the primary cardiac end point in the CLAS.The article reports on the baseline comparability of the two treatment groups for some variables in Tables 1 and 2. However, the article does not report on the baseline comparability of the two treatment groups with respect to

×